Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 7/20 | 0.35 |
| ▸ | KDM6B | O15054 | 6/20 | 0.35 |
| ▸ | KDM5C | P41229 | 6/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.35 |
| ▸ | KDM3A | Q9Y4C1 | 5/20 | 0.35 |
| ▸ | KDM4A | O75164 | 3/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | KDM5A | P29375 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 3/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23211127 | 0.93 | FFAR1 (0.41) | FFAR1KDM2AKDM5CKDM4CUSP30 | |
| SCHEMBL23211118 | 0.93 | FFAR1 (0.41) | FFAR1KDM2AKDM5CKDM4CUSP30 | |
| SCHEMBL16342703 | 0.93 | FFAR1 (0.41) | FFAR1KDM2AKDM5CKDM4CUSP30 | |
| SCHEMBL2363986 | 0.88 | FFAR1 (0.44) | FFAR1USP30ACHE | |
| SCHEMBL21858191 | 0.86 | FFAR1 (0.38) | FFAR1USP30KDM4E | |
| SCHEMBL320321 | 0.86 | FFAR1 (0.42) | FFAR1USP30KDM5AACHE | |
| SCHEMBL12539259 | 0.86 | USP30 (0.51) | FFAR1USP30HSD11B1 | |
| SCHEMBL1425500 | 0.86 | USP30 (0.51) | FFAR1USP30HSD11B1 | |
| SCHEMBL1425502 | 0.86 | USP30 (0.51) | FFAR1USP30HSD11B1 | |
| SCHEMBL23242984 | 0.83 | FFAR1 (0.38) | FFAR1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481524-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-07-09 | — | — | US | disclosed |
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136789-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | FFAR1 2619/4885KDM2A 1291/4885KDM6B 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.